Filtered By:
Source: Cancer Control
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 661 results found since Jan 2013.
Regulatory circuits of mitophagy restrict distinct modes of cell death during memory CD8 < sup > + < /sup > T cell formation
Sci Immunol. 2023 Sep 29;8(87):eadf7579. doi: 10.1126/sciimmunol.adf7579. Epub 2023 Sep 22.ABSTRACTMitophagy, a central process guarding mitochondrial quality, is commonly impaired in human diseases such as Parkinson's disease, but its impact in adaptive immunity remains unclear. The differentiation and survival of memory CD8+ T cells rely on oxidative metabolism, a process that requires robust mitochondrial quality control. Here, we found that Parkinson's disease patients have a reduced frequency of CD8+ memory T cells compared with healthy donors and failed to form memory T cells upon vaccination against COVID-19, highli...
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Fabien Franco Alessio Bevilacqua Ruey-Mei Wu Kung-Chi Kao Chun-Pu Lin Lor ène Rousseau Fu-Ti Peng Yu-Ming Chuang Jhan-Jie Peng Jaeoh Park Yingxi Xu Antonino Cassotta Yi-Ru Yu Daniel E Speiser Federica Sallusto Ping-Chih Ho Source Type: research
Harnessing Dendritic Cells: Next Frontier for Durable Immune Control in Myeloma
Clin Cancer Res. 2023 Sep 22:OF1-OF3. doi: 10.1158/1078-0432.CCR-23-2292. Online ahead of print.ABSTRACTImmune-based approaches including T-cell redirection have transformed the therapeutic landscape in myeloma. Injection of dendritic cells (DC) led to the induction of immune responses in vaccinated patients with myeloma. These studies pave the way for future combination strategies harnessing DCs to enhance tumor immunity and improve outcomes in myeloma. See related article by Freeman et al., p. 000.PMID:37737650 | DOI:10.1158/1078-0432.CCR-23-2292
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Madhav V Dhodapkar Source Type: research
Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma
CONCLUSIONS: Two doses of DC:Ad-S, one given immediately before and another after ASCT, were feasible and safe. A high frequency of vaccine-specific immune responses was seen in combination with durable clinical outcomes, supporting ongoing investigation into the potential of this approach.PMID:37735756 | DOI:10.1158/1078-0432.CCR-22-3987
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Ciara L Freeman Reginald Atkins Indumathy Varadarajan Meghan Menges Jeffrey Edelman Rachid Baz Jason Brayer Omar Castaneda Puglianini Jose Leonel Ochoa-Bayona Taiga Nishihori Kenneth H Shain Bijal Shah Dung Tsa Chen Linda Kelley Domenico Coppola Melissa A Source Type: research
A H3K27M-targeted vaccine in adults with diffuse midline glioma
Nat Med. 2023 Sep 21. doi: 10.1038/s41591-023-02555-6. Online ahead of print.ABSTRACTSubstitution of lysine 27 to methionine in histone H3 (H3K27M) defines an aggressive subtype of diffuse glioma. Previous studies have shown that a H3K27M-specific long peptide vaccine (H3K27M-vac) induces mutation-specific immune responses that control H3K27M+ tumors in major histocompatibility complex-humanized mice. Here we describe a first-in-human treatment with H3K27M-vac of eight adult patients with progressive H3K27M+ diffuse midline glioma on a compassionate use basis. Five patients received H3K27M-vac combined with anti-PD-1 treat...
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Niklas Grassl Isabel Poschke Katharina Lindner Lukas Bunse Iris Mildenberger Tamara Boschert Kristine J ähne Edward W Green Ingrid H ülsmeyer Simone J ünger Tobias Kessler Abigail K Suwala Philipp Eisele Michael O Breckwoldt Peter Vajkoczy Oliver M Gra Source Type: research
Prevalence of hepatitis B infection in the Gambian population: A narrative review of recent developments
This study reviewed the recent trends in the epidemiological characteristics of HBV in the Gambia. The researchers conducted an online literature search for primary studies on HBV prevalence published in the past two decades from Jan 1992 to Feb 2022 inclusive on Google Scholar, PubMed, and Scopus. All retrieved studies were assessed for eligibility according to specific inclusion/exclusion criteria, data completeness, and methodological coherence. We found that HBV infection prevalence is above 8% in The Gambia. Moreover, HBV is the most common cause of hepatocellular carcinoma (HCC) in Gambia. Liver cirrhosis and HCC hav...
Source: Cancer Control - September 18, 2023 Category: Cancer & Oncology Authors: Muhammed Camara Marcarious M Tantuoyir SeyedAhmad SeyedAlinaghi Fereshteh Ghiasvand Zahra Ahmadinejad Source Type: research
NLGN4X TCR transgenic T cells to treat gliomas
CONCLUSION: NLGN4X-TCR-T demonstrates efficacy in a preclinical glioblastoma model. On a global scale, we provide first evidence for the therapeutic retrieval of vaccine-induced human TCRs for the off-the-shelf treatment of glioblastoma patients.PMID:37715782 | DOI:10.1093/neuonc/noad172
Source: Cancer Control - September 16, 2023 Category: Cancer & Oncology Authors: C Kr ämer M Kilian Y C Chih A Kourtesakis D C Hoffmann T Boschert P Koopmann K Sanghvi A De Roia S Jung K J ähne B Day L D Shultz M Ratliff R Harbottle E W Green R Will W Wick M Platten L Bunse Source Type: research
Association of vaccine-specific regulatory T cells with reduced antibody response to repeated influenza vaccination
This article is protected by copyright. All rights reserved.PMID:37713727 | DOI:10.1002/eji.202350525
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Pin-Hung Lin Po-Ju Hsiao Ching-Fu Pan Ming-Tsan Liu Jann-Tay Wang Chi Ching Fang-Yi Wu Yi-Hsuan Lin Yu-Chan Yang Le-Yin Hsu Hung-Chih Yang Un-In Wu Source Type: research
Control groups for HIV prevention efficacy trials: what does the future hold?
Curr Opin HIV AIDS. 2023 Sep 12. doi: 10.1097/COH.0000000000000818. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Ending the HIV epidemic will require the development of additional effective immune-mediated and nonimmune-mediated means of HIV prevention. Evaluating novel interventions requires large, controlled trials demonstrating efficacy. Recent advances in the field of HIV prevention necessitate new approaches to efficacy trial design.RECENT FINDINGS: Three classes of efficacy trial designs are possible: standard of prevention-controlled trials, active-controlled trials, and active-controlled trials augmented with e...
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Holly Janes Susan Buchbinder Source Type: research
Self-assembling Gn head ferritin nanoparticle vaccine provides full protection from lethal challenge of < em > Dabie bandavirus < /em > in aged ferrets
This study demonstrates that DBV GnH-FT nanoparticles provide an efficient vaccine efficacy in mouse and aged ferret models and should be an outstanding vaccine candidate targeted for the aged population against fatal DBV infection. IMPORTANCE Dabie bandavirus (DBV) is an emerging tick-borne virus that causes severe fever with thrombocytopenia syndrome (SFTS) in infected patients. Human SFTS symptoms progress from fever, fatigue, and muscle pain to the depletion of white blood cells and platelets with fatality rates up to 30%. The recent spread of its vector tick to over 20 states in the United States increases the potenti...
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Dokyun Kim Eunha Kim Semi Kim Youseung Chung Chih-Jen Lai Inho Cha Sung-Dong Cho Yunseo Choi Xinghong Dai Stephanie Kim Seokmin Kang Mi-Jeong Kwak Ziyi Liu Younho Choi Su-Hyung Park Young Ki Choi Jae U Jung Source Type: research
Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy
CONCLUSION: This triple combining in situ vaccine induced intensive antitumor responses, mediated effective systemic tumor control and survival benefit, and displayed impressive synergistic antitumor effect with checkpoint blockade therapy. These data preliminary confirmed the efficacy, feasibility and safety of the triple combining in situ vaccine, suggesting its great application potential as both monotherapy and a part of combined immunotherapeutic regimens in clinical scenario.PMID:37700338 | DOI:10.1186/s12967-023-04504-w
Source: Cancer Control - September 12, 2023 Category: Cancer & Oncology Authors: Zhichen Sun Yanhong Chu Jie Xiao Yueling Yang Fanyan Meng Xinyue Wang Yanbing Dong Junmeng Zhu Yirong Wu Lanqun Qin Yaohua Ke Baorui Liu Qin Liu Source Type: research
An update on one-dose HPV vaccine studies, immunobridging and humoral immune responses - A meeting report
This report summarises the discussions and lessons learned on two topics: an update on one-dose HPV vaccination studies and humoral immune responses upon HPV vaccination. Long-term follow-up studies from Costa Rica (eleven years) and India (ten years) report stable levels of antibodies after a single HPV vaccination. High vaccine effectiveness against incident persistent HPV 16/18 infection was seen in India (95.4%, 85.0-99.9) ten years postvaccination and in Kenya (97.5%, 81.7-99.7) eighteen months postvaccination, an important observation in a setting with a higher HPV prevalence. The potential impact of HPV vaccination ...
Source: Cancer Control - September 8, 2023 Category: Cancer & Oncology Authors: Dur-E-Nayab Waheed F Ricardo Burdier Carina Eklund Iacopo Baussano Filipe Cola ço Mariz Laura T éblick Nelly Mugo Deborah Watson-Jones Margaret Stanley Marc Baay Alex Vorsters Source Type: research
Developments in targeted therapy & amp; immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review
CONCLUSIONS: This review encompasses the latest updates in targeted therapy and immunotherapy in lung cancer management and discusses the future direction in the field.PMID:37675321 | PMC:PMC10477626 | DOI:10.21037/atm-22-4444
Source: Cancer Control - September 7, 2023 Category: Cancer & Oncology Authors: Molly S C Li Kevin K S Mok Tony S K Mok Source Type: research
DeepMHCI: An anchor position-aware deep interaction model for accurate MHC-I peptide binding affinity prediction
Bioinformatics. 2023 Sep 5:btad551. doi: 10.1093/bioinformatics/btad551. Online ahead of print.ABSTRACTMOTIVATION: Computationally predicting MHC-I peptide binding affinity is an important problem in immunological bioinformatics, which is also crucial for the identification of neoantigens for personalized therapeutic cancer vaccines. Recent cutting-edge deep learning-based methods for this problem cannot achieve satisfactory performance, especially for non-9-mer peptides. This is because such methods generate the input by simply concatenating the two given sequences: a peptide and (the pseudo sequence of) an MHC class I mo...
Source: Cancer Control - September 5, 2023 Category: Cancer & Oncology Authors: Wei Qu Ronghui You Hiroshi Mamitsuka Shanfeng Zhu Source Type: research
Corrigendum to "Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: A systematic review and meta-analysis" Vaccine 40(41) (2022) 5971-5996
Vaccine. 2023 Sep 1:S0264-410X(23)00787-9. doi: 10.1016/j.vaccine.2023.06.084. Online ahead of print.NO ABSTRACTPMID:37659892 | DOI:10.1016/j.vaccine.2023.06.084
Source: Cancer Control - September 2, 2023 Category: Cancer & Oncology Authors: Matthew Palmer Kota Katanoda Eiko Saito Cecilia Acuti Martellucci Shiori Tanaka Sayaka Ikeda Haruka Sakamoto Dorothy Machalek Julia M L Brotherton Jane S Hocking Source Type: research
Graphene oxide nanoarchitectures in cancer therapy: Drug and gene delivery, phototherapy, immunotherapy, and vaccine development
Environ Res. 2023 Aug 31:117027. doi: 10.1016/j.envres.2023.117027. Online ahead of print.ABSTRACTThe latest advancements in oncology involves the creation of multifunctional nanostructures. The integration of nanoparticles into the realm of cancer therapy has brought about a transformative shift, revolutionizing the approach to addressing existing challenges and limitations in tumor elimination. This is particularly crucial in combating the emergence of resistance, which has significantly undermined the effectiveness of treatments like chemotherapy and radiotherapy. GO stands as a carbon-derived nanoparticle that is incre...
Source: Cancer Control - September 2, 2023 Category: Cancer & Oncology Authors: Mohammad Saleh Sadeghi Faezeh Hosseini Sangrizeh Negar Jahani Mahdi Sadegh Abedin Soheila Chaleshgari Alireza Khodaei Ardakan Reza Baeelashaki Golnaz Ranjbarpazuki Parham Rahmanian Mohammad Arad Zandieh Noushin Nabavi Amir Reza Aref Shokooh Salimimoghadam Source Type: research
